CI
ALNY icon

Cowen Inc’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cowen Inc’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5,700
Closed -$670K – 293
2017
Q3 		$670K Buy
+5,700
New +$487K 0.02% 147
2017
Q1 		– Sell
-11,200
Closed -$518K – 237
2016
Q4 		$419K Buy
11,200
+7,200
+180% +$301K 0.02% 198
2016
Q3 		$271K Buy
+4,000
New +$282K 0.02% 202
2015
Q4 		– Sell
-3,950
Closed -$317K – 299
2015
Q3 		$317K Buy
+3,950
New +$439K 0.02% 195

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Cowen Inc's ALNY Position: Q4 2017 in Review

Cowen Inc sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2017, closing a stake of 5,700 shares — an estimated $670K sold.

Cowen Inc first reported a position in ALNY in Q3 2015 and held it in 4 quarters. The position peaked at $670K in Q3 2017. 282 funds tracked by Wall St. Rank hold ALNY as of Q4 2017.

  • Cowen Inc reported no remaining Alnylam Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Cowen Inc sold 5,700 Alnylam Pharmaceuticals shares in Q4 2017, an estimated $670K.
  • Cowen Inc first reported a position in Alnylam Pharmaceuticals in Q3 2015 and held it in 4 quarters.
  • Cowen Inc's Alnylam Pharmaceuticals position peaked at $670K in Q3 2017.
  • 282 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2017.

Based on Cowen Inc's 13F filing for Q4 2017, filed 15 Feb 2018.